Drug Profile
Research programme: ROR1 inhibitors - Oncternal Therapeutics, Inc.
Alternative Names: Receptor tyrosine protein kinase like orphan receptor inhibitors - Oncternal Therapeutics, Inc.; ROR1 CAR-NK cell therapy - Oncternal Therapeutics, IncLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Oncternal Therapeutics, Inc.; University of California, San Diego
- Class Antibodies; Antineoplastics; Bispecific antibodies; CAR-NK cell therapies; Gene therapies; Immunoconjugates; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; Receptor tyrosine kinase-like orphan receptor antagonists; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 23 Mar 2023 Oncternal Therapeutics has patent protection for methods of screening for antibodies that specifically bind to ROR1 in USA
- 23 Mar 2023 Oncternal Therapeutics has patent protection for non-zilovertamab ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-zilovertamab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors in USA